Vanda Pharmaceuticals

VNDA · NASDAQ

$4.17+$0.08 (+1.96%)TodayMarket closed · Oct 20, 7:54 PM ET

Prev close $4.09

About VNDA

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 533 full-time employees. The company went IPO on 2006-04-12. The firm's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Employees: 533
Headquarters: WASHINGTON, Washington Dc
Listed: Apr 12, 2006
Sector: Health Care
Industry: Biotechnology
Website: vandapharma.com

Leadership

Vanda Pharmaceuticals executives
Name	Title	Since	Age
Mihael Polymeropoulos	—	2003	65
Kevin Moran	—	—	41
Joakim Wijkstrom	—	—	59
Timothy Williams	—	—	49
Gunther Birznieks	—	—	56
Richard Dugan	—	—	83
Phaedra Chrousos	—	—	45
Tage Honore	—	—	74
Stephen Mitchell	—	—	73
Anne Ward	—	—	53

Revenue by product and region

Fiscal year ended Dec 31, 2024: $198.77M total revenue

By product

Fanapt® net product sales$94.30M47.4%
HETLIOZ® net product sales$76.67M38.6%
PONVORY® net product sales$27.80M14.0%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Vanda Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Formosa Laboratories	Supplier	TW	0.58
Thermo Fisher Scientific TMO	Supplier and customer	US	0.05
Novartis NOVN.SW	Supplier and customer	CH	-0.15
Cardinal Health CAH	Customer	US	-0.37
Omnicom OMC	Supplier	US	-0.44
Cigna CI	Customer	US	-0.61
Bristol-Myers Squibb BMY	Supplier and customer	US	-0.69
Eli Lilly LLY	Supplier and customer	US	-0.71
UnitedHealth Group UNH	Customer	US	-0.77
Sanofi SAN.PA	Supplier and customer	FR	-0.78

Similar companies

Companies in the same industry as Vanda Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.